🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Data from the MOTIVATE study in ITI in #haemophilia A. Focusing on the reasons why & how clinicians are conducting ITI & associated outcomes #ISTH2025

SV003 first triple specific antibody for #haemophilia A treatment. 10 x potency of emicizumab. Given subcut, in vivo & in vitro models showed positive results & human studies are due to start 2026. This is a high yield, low cost production molecule. #ISTH2025

Final report from the haemnet team #VWD360 study. 611 participants from 15 countries, even split in gender.ean bleed of 1.33 per week but with range 0-10. A reflection of the true burden of VWD on physical, emotional & social wellbeing #ISTH2025

NEWS: At #ISTH2025, we presented promising sutacimig Phase 2 interim results for Glanzmann thrombasthenia (GT), as well as HMB-002 data in Von Willebrand disease (VWD). HIGHLIGHTS: • Sutacimig (formerly HMB-001) – Phase 2 interim results demonstrated a greater than 50%

Cathy Harrison 💙 Dr Kate Khair PhD Time to stop calling VWD a mild disease. The best 100 years birthday present we can give people living w VWD is listen to their lived experience and start pushing for innovation and leapfrog prophylaxis into the 21st century hemab.com/news-items/hem… Hemab Therapeutics

Melanie Daniel gave a great presentation on the unbiased assessment of VWD burden and healthcare consumption using pseudonymized big data! It is important to see such a high number of well charcterized VWD patients with 14 years long follow-up! #ISTH2025 Melanie Daniel

Great advice to new interns. Dr. Glaucomflecken Dr. Brian Goldman EM:RAP

Von Willebrand disease (VWD) deserves its own path forward. Care for VWD should begin with a true understanding of the condition and the lived experiences of those affected. We’re on to something different with HMB-002. To learn more or enroll in our trial, contact us at

I am excited to announce that I am recruiting a Post Doc to join my team University of Leeds LICAMM! If you are interested in #fibrinogen, #microscopy and #thrombosis check this out: jobs.leeds.ac.uk/Vacancy.aspx?r… Thank you British Heart Foundation for the funding!

Catch up with five episodes of our #Haemcast miniseries, in conversation with Terence O'Rourke about living with severe #haemophilia over eight decades. Part 6 is due out soon! Stream, download and listen here: loom.ly/A4UWu6M #livedexperience #podcast #bleedingdisorders

Do you remember when you joined X? I didn’t but Twitter did! #MyXAnniversary

I found myself getting angry during a work meeting last week. Over coffee, a colleague told me about a skeptical physician who spoke up during a hematology meeting and dismissed the idea that patients with von Willebrand Disease were in need of treatment. Sadly, I'm not

At #ISTH2025 our message was clear: progress isn’t just possible – it’s happening. Promising data, fresh perspectives, and real collaboration are driving meaningful steps forward for the underrepresented bleeding disorder community. We’re urgently focused on a better future.

Simon Fletcher is on the latest Gene Therapy segment discussing the mystique of gene therapy. bit.ly/thebloodstream… Presenting Sponsor: #Takeda It’s a Whole New World brought to you by CSL Behring #bloodstreammedia #raredisease #genetherapy

Last week, we launched 'Underserved, Overlooked: How our health systems are failing women and girls with a bleeding disorder' at the Houses of Parliament. A huge thanks to everyone that attended the event, The report is available to download at lnkd.in/e2RxEG68

This week on the Haemnet blog, community advocate Rich Gorman reflects on a report from a multidisciplinary expert discussion on virtual care in haemophilia, published in The Journal of Haemophilia Practice. Find out more here: loom.ly/k_d1RDk

Victims of UK infected blood scandal being "harmed further" by compensation delays, says inquiry chair bbc.in/4eD05oa

ICYMI: Hemab CEO Benny Sorensen sat down with Dr. Guy Young, Director of the Hemostasis and Thrombosis Center at Children's Hospital Los Angeles, to reflect on two decades of progress, and what's still needed, for underserved bleeding disorders. Watch the conversation below and

Soaking up the sun by the seaside? Staycationing or going global? Peak summer holiday time is creeping closer. It’s often a time for winding down and relaxing – but we’re looking forward to a busy summer full of projects and planning. What are your summer plans?

🎥 “It was a happy accident.” Dr. Catherine Rea reflects on how the pandemic revealed stark differences in care between those with multiple treatment options and those without, and how that experience led her to Hemab. Watch as she reflects on her move from observing urgent